Contrasting Aeon Global Health (AGHC) and Its Rivals

Aeon Global Health (OTCMKTS: AGHC) is one of 23 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its peers? We will compare Aeon Global Health to related businesses based on the strength of its profitability, valuation, institutional ownership, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aeon Global Health and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aeon Global Health 0 0 1 0 3.00
Aeon Global Health Competitors 132 563 664 36 2.43

As a group, “Medical laboratories” companies have a potential upside of 3.74%. Given Aeon Global Health’s peers higher possible upside, analysts plainly believe Aeon Global Health has less favorable growth aspects than its peers.

Earnings & Valuation

This table compares Aeon Global Health and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aeon Global Health $16.30 million -$8.00 million -0.61
Aeon Global Health Competitors $1.13 billion $90.54 million 432.90

Aeon Global Health’s peers have higher revenue and earnings than Aeon Global Health. Aeon Global Health is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Aeon Global Health and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aeon Global Health -43.04% -337.14% -61.39%
Aeon Global Health Competitors -103.54% -222.38% -36.27%

Risk & Volatility

Aeon Global Health has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Aeon Global Health’s peers have a beta of 1.37, meaning that their average stock price is 37% more volatile than the S&P 500.

Institutional and Insider Ownership

52.0% of shares of all “Medical laboratories” companies are held by institutional investors. 11.5% of Aeon Global Health shares are held by company insiders. Comparatively, 17.4% of shares of all “Medical laboratories” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aeon Global Health peers beat Aeon Global Health on 10 of the 13 factors compared.

About Aeon Global Health

AEON Global Health Corp., together with its subsidiaries, provides various clinical laboratory testing services in the United States. The company operates through two segments, Laboratory Testing Services and Web-Based Software. Its laboratory testing services include the testing of an individual's blood, urine, or saliva for the presence of drugs or chemicals, as well as the patient's DNA profile. The company primarily offers medical toxicology, DNA pharmacogenomics, cancer genetic testing, and molecular biology tests. It also provides Web-based services as software as a service for Web-based revenue cycle management applications; and telehealth products and services that enable healthcare organizations to coordinate care for patients, and enhance related administrative and clinical workflows, and compliance with regulatory requirements. In addition, AEON Global Health Corp. offers post contract customer support services. The company was formerly known as Authentidate Holding Corp. and changed its name to AEON Global Health Corp. in January 2018. AEON Global Health Corp. is based in Gainesville, Georgia.

Receive News & Ratings for Aeon Global Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeon Global Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply